Investing
Also, a startup from Melbourne has raised $1 million in pre-seed funding for its chemotherapy dosing AI.
The funds will be used to increase the company's development into new automated orthopedic indications and deploy its manufacturing model.
The company will use the funds to broaden its product line and boost recruitment.
The company will scale its weight loss offerings ahead of generic GLP-1s coming to the Canadian market in 2026.
Matt Faustman, Honey Health's founder and CEO, said that in 2026 organizations will be looking for an operational platform instead of narrow point solutions.
The company will use the funds to grow its UK presence, expand its workforce, advance research and patient experience efforts, and enhance its data-driven care platform.
The funds will be used to accelerate the company's growth of administrative, operational and clinical AI agents.
The latest round brings the company's total funding to more than $50 million.
A report by Silicon Valley Bank says that by the end of 2025, $18.5 billion is expected to be invested in healthtech.
Also, a new AI-driven genomics platform developed in Queensland can identify cancer biomarkers and predict tumour responses to chemotherapy.